Abstract
Background Serum uric acid (SUA) level is the strongest determinant of gout, and the relationship between hyperuricemia and gout has been found. However, the association between the across-full range of SUA level and gout also remains uncertain. We aimed to investigate the trend across an across-full range of SUA level and gout in the general population.
Materials and Methods This study included 4,738 US adults from The National Health and Nutrition Examination Survey (NHANES). A generalized additive model was used to fit the non-linear trend between SUA level and gout.
Results 2,209 males and 2,469 females were included in our study, with the age range of 20∼80 years. The range of SUA level was from 0.8 to 15.1 mg/dL. About 5.9% of participants had gout. There was a U-shape association between SUA level and gout in univariable GAM (EDF = 3.881, p <0.001) and multivariable GAM (EDF = 3.795, p <0.001). The lowest risk of gout was observed in participants with SUA level of 5-6mg/dL. We evaluated the trend of SUA level with gout by gender. Both males and females with high SUA level have a high prevalence of gout. Male have a high prevalence of gout with low SUA level. The SUA level and prevalence of gout support a U-shape in males, while females show a linear shape.
Conclusion This study showed that low as well as high SUA are associated with gout. Hypouricemia is a candidate predictor of gout in US adults.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by grants from the National Natural Science Foundation of China (NO. 82173753,81373083), Si chuan province aged and elderly health collaborative innovation center project in (NO. YLZBZ2004), General scientific research project of Chengdu Medical College (No. CYZYB20-02).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All NHANES protocols were approved by the National Centre for Health Statistics Research ethics review board.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data are available in a public, open access repository. The datasets for this study can be found in https://wwwn.cdc.gov/Nchs/Nhanes/2017-2018/index.htm.
